Orphazyme A (ORPH) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access ORPH Annual Income Statement →
The income statement data below highlights shifts in Orphazyme A's operating performance over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2021)
Q4 2021
0 0 0 (Dec 31 2020)
Revenues
Total Revenue36.19
Costs & Expenses
Gross Profit36.19
Selling, Administration, Marketing339.52
Research and Development Expense329.98
Other Operating Expense / -Income0.00
Total operating costs including COS669.50
Operating income / -loss-633.30
Net Interest Expense / -Income0.00
Other loss / -income-1.82
Total costs & expenses667.67
Income & Taxes
Income / -loss before income taxes-631.48
Income taxes expenses / -benefit-4.94
Income after income taxes-626.54
Income / -loss from continuing operations-626.54
Net income / -loss-626.54
Income / -loss to shareholder-626.54
EBIT-631.48
EBITD-631.48
EBITDA-631.48
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)34.92
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)34.92
4 historic quarters locked

Sign in to unlock the full Orphazyme A income statement history.

About ORPH Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.